AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24227660 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 376
Study 24227660 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 376
Study 24227660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 23055513 — intervention group
Group type: EXPERIMENTAL
Intervention: Early visual cortex responses to varying stimulation rates
Number of subjects: 0
Study 23055513 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle- and higher-tier regions of the ventral visual stream
Number of subjects: 0
Study 23055513 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention during incidental task
Number of subjects: 0
Study 19357528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (236+/‐150 mg/day)
Number of subjects: 51
Study 19357528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17855483 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-788 (ETB receptor blockade)
Number of subjects: 16
Study 17855483 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-788 and BQ-123 (combined ET receptor blockade)
Number of subjects: 16
Study 17855483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17855483 — intervention group
Group type: COMPARATOR
Intervention: BQ-123 (ETA receptor blockade)
Number of subjects: 16
Study 15881863 — intervention group
Group type: EXPERIMENTAL
Intervention: New Livfit (NLF)
Number of subjects: 0
Study 15881863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12030661 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina Plan (cognitive behavioural disease management programme)
Number of subjects: 142
Study 12030661 — intervention group
Group type: COMPARATOR
Intervention: Routine practice nurse‐led secondary prevention educational session
Number of subjects: 142
Study 9583767 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia after buprenorphine treatment
Number of subjects: 0
Study 9583767 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo respiratory depression after buprenorphine treatment
Number of subjects: 0
Study 7662835 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianginal drug
Number of subjects: 0
Study 7662835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2128879 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily injections or pulsatile subcutaneous administration of human menopausal gonadotropin (hMG)
Number of subjects: 0
Study 2128879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and bromocriptine
Number of subjects: 0
Study 2128879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and hMG
Number of subjects: 0
Study 2128879 — intervention group
Group type: EXPERIMENTAL
Intervention: Various clinical conditions and types of preparations administered
Number of subjects: 0
Study 533574 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antipyrine treatment over 4 or 5 weeks in vegetarian Asians and non-vegetarians
Number of subjects: 44
Study 533574 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antipyrine treatment
Number of subjects: 44
Study 533574 — intervention group
Group type: COMPARATOR
Intervention: Caucasian non-vegetarian group
Number of subjects: 44
Study 30148161 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (PHF) 750 mg/d in three doses for 90 days
Number of subjects: 36
Study 27038769 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 0
Study 24106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 25 µg
Number of subjects: 20
Study 24106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 50 µg
Number of subjects: 20
Study 24106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg
Number of subjects: 20
Study 24106334 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg
Number of subjects: 20
Study 24106334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22920408 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice and referral for Brief Intervention
Number of subjects: 0
Study 22920408 — intervention group
Group type: COMPARATOR
Intervention: Leaflet on healthy living (Control)
Number of subjects: 0
Study 20386480 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 25
Study 20386480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 25
Study 20386480 — intervention group
Group type: EXPERIMENTAL
Intervention: No stretching
Number of subjects: 25
Study 17296323 — intervention group
Group type: COMPARATOR
Intervention: Patellar taping
Number of subjects: 32
Study 17296323 — intervention group
Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 32
Study 16265778 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-IP (omega-3 fatty acid, 3 g/day)
Number of subjects: 31
Study 16265778 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-IP (omega-6 fatty acid, 9 g/day)
Number of subjects: 31
Study 16265778 — intervention group
Group type: COMPARATOR
Intervention: Control (prednisolone 40 mg for 1 week, tapering by 5 mg/week)
Number of subjects: 31
Study 12053586 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test with unconjugated penicillin
Number of subjects: 46
Study 12053586 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test with penicillin‐polylysine
Number of subjects: 46
Study 12053586 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test with penicillin conjugated to human serum albumin
Number of subjects: 46
Study 12053586 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test (overall)
Number of subjects: 46
Study 12053586 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 46
Study 10814677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture II (HCII) assay
Number of subjects: 2944
Study 10814677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture I (HCI) assay
Number of subjects: 2944
Study 10814677 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 2944
Study 10814677 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing (HCII)
Number of subjects: 2944
Study 10814677 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 2944
Study 8634560 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg twice daily for two weeks
Number of subjects: 174
Study 8634560 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 174
Study 8634560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 2054264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (300 mg)
Number of subjects: 8
Study 2054264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (600 mg)
Number of subjects: 8
Study 2054264 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrum Forte (combination tablet)
Number of subjects: 8
Study 6094434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 68
Study 6094434 — intervention group
Group type: COMPARATOR
Intervention: Penicillin-gentamicin
Number of subjects: 68
Study 31370976 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dose of buprenorphine (100%)
Number of subjects: 7
Study 31370976 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% of usual daily dose of buprenorphine
Number of subjects: 7
Study 31370976 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% of usual daily dose of buprenorphine
Number of subjects: 7
Study 29499728 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic visceral manipulation (OVM) for 15 min once per week for six weeks
Number of subjects: 76
Study 29499728 — intervention group
Group type: COMPARATOR
Intervention: Sham osteopathic visceral manipulation (SOVM) once per week for six weeks
Number of subjects: 76
Study 27278054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 44
Study 27278054 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 44
Study 26117356 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 15
Study 22261849 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic CO(2) laser resections combined with mitomycin‐C and/or triamcinolone acetonide therapy
Number of subjects: 11
Study 22261849 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐term oral steroid and immunosuppressive therapy as well as the use of proton pump inhibitors
Number of subjects: 11
Study 19622596 — intervention group
Group type: COMPARATOR
Intervention: XELOX(30)
Number of subjects: 141
Study 19622596 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX(30Chron)
Number of subjects: 141
Study 18614936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min passive stretching (PS2)
Number of subjects: 13
Study 18614936 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 min passive stretching (PS4)
Number of subjects: 13
Study 18614936 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 min passive stretching (PS8)
Number of subjects: 13
Study 18614936 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) with no stretching
Number of subjects: 13
Study 15854235 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 62
Study 15854235 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 62
Study 11815507 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide taken before each of the three main meals
Number of subjects: 19
Study 11815507 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide taken before breakfast and before the evening meal
Number of subjects: 19
Study 10401941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg q.i.d. for 3 days)
Number of subjects: 60
Study 10401941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7722951 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (Warm Touch, Mallinckrodt Medical, Inc, St Louis, MO)
Number of subjects: 29
Study 7722951 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal care
Number of subjects: 29
Study 7722951 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 29
Study 7722951 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature measurement sites (bladder, oral cavity, rectum, tympanic membrane)
Number of subjects: 29
Study 2327747 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g every 12 h for four doses) with Tobramycin (2 mg/kg)
Number of subjects: 12
Study 2327747 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g every 12 h for four doses) with Netilmicin (2 mg/kg)
Number of subjects: 12
Study 2327747 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (4 g single dose)
Number of subjects: 12
Study 6353840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine without adrenaline
Number of subjects: 0
Study 6353840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 0
Study 6353840 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine without adrenaline
Number of subjects: 0
Study 6353840 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine with adrenaline
Number of subjects: 0
Study 31362773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein (LC/HP) dietary intervention (30% total energy as protein, 1.6 g/kg per day, carbohydrate-to-protein ratio < 1.5, fat intake at 30% of total energy)
Number of subjects: 100
Study 31362773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention, regular daily diets)
Number of subjects: 100
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric tablets with high-protein meal
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-enteric tablets
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder capsules
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Kwai garlic powder tablets
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (boiled)
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (roasted)
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (pickled)
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (acid-minced)
Number of subjects: 13
Study 29937536 — intervention group
Group type: EXPERIMENTAL
Intervention: Black garlic
Number of subjects: 13
Study 29937536 — intervention group
Group type: COMPARATOR
Intervention: Control (homogenized raw garlic)
Number of subjects: 13
Study 26632655 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nerve-sparing radical hysterectomy (LNRH)
Number of subjects: 120
Study 26632655 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 120
Study 23490397 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tooth implants
Number of subjects: 25
Study 23490397 — intervention group
Group type: COMPARATOR
Intervention: Natural teeth
Number of subjects: 25
Study 21404051 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20
Study 21404051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with CoQ (Med+CoQ diet)
Number of subjects: 20
Study 21404051 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid‐rich diet (SFA diet)
Number of subjects: 20
Study 19942722 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 5)
Number of subjects: 13
Study 19942722 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (n = 4)
Number of subjects: 13
Study 19942722 — intervention group
Group type: COMPARATOR
Intervention: Music therapy (n = 4)
Number of subjects: 13
Study 21665421 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node clearance (ALNC)
Number of subjects: 625
Study 21665421 — intervention group
Group type: COMPARATOR
Intervention: No axillary lymph node clearance (no-Ax)
Number of subjects: 625
Study 15983684 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneum
Number of subjects: 79
Study 15983684 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure of the peritoneum
Number of subjects: 79
Study 12512851 — intervention group
Group type: EXPERIMENTAL
Intervention: Invulnerability undermined (IU) condition
Number of subjects: 128
Study 12512851 — intervention group
Group type: COMPARATOR
Intervention: Demand characteristic control (DCC) condition
Number of subjects: 128
Study 10412777 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive therapy (SIT)
Number of subjects: 15
Study 10412777 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intermittent therapy (LIT)
Number of subjects: 15
Study 10412777 — intervention group
Group type: COMPARATOR
Intervention: Before SIT
Number of subjects: 15
Study 10412777 — intervention group
Group type: COMPARATOR
Intervention: After SIT
Number of subjects: 15
Study 7718750 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (PF) anesthesia
Number of subjects: 30
Study 7718750 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-fentanyl (IF) anesthesia
Number of subjects: 30
Study 2202852 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 64
Study 2202852 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 64
Study 6456668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mezlocillin (16 gm/day)
Number of subjects: 70
Study 6456668 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (8 gm/day)
Number of subjects: 70
Study 6456668 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (2 gm/day) added if patients failed to improve within 48 hours
Number of subjects: 70
Study 29282336 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF neurofilament light chain (NfL)
Number of subjects: 50
Study 29282336 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF phosphorylated tau 181 (p-tau)
Number of subjects: 50
Study 29282336 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF tau
Number of subjects: 50
Study 29282336 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF NfL/p-tau ratio
Number of subjects: 50
Study 29282336 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF NfL
Number of subjects: 50
Study 29282336 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma NfL
Number of subjects: 50
Study 26938333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg taken twice daily (n = 48)
Number of subjects: 89
Study 26938333 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg daily (n = 41)
Number of subjects: 89
Study 23640543 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-Assisted Problem Solving (CAPS)
Number of subjects: 132
Study 23640543 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study 21820247 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 75-150 μg/d administration
Number of subjects: 8
Study 21820247 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan depletion (TD)
Number of subjects: 8
Study 20163267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative systemic agents to first‐line antimonials
Number of subjects: 0
Study 20163267 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced topical paromomycin preparation
Number of subjects: 0
Study 20163267 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Number of subjects: 0
Study 20163267 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 0
Study 20163267 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy and immunomodulators
Number of subjects: 0
Study 20163267 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies of several drugs
Number of subjects: 0
Study 18550360 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple interventions
Number of subjects: 101
Study 18550360 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex interventions
Number of subjects: 101
Study 18550360 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruistic views
Number of subjects: 101
Study 18550360 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial design factors
Number of subjects: 101
Study 18550360 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate
Number of subjects: 101
Study 15907756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses and physicians' beliefs about dietary restrictions in epilepsy
Number of subjects: 250
Study 15907756 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal experience with dietary restrictions
Number of subjects: 250
Study 15907756 — intervention group
Group type: EXPERIMENTAL
Intervention: Common foods reported by participants
Number of subjects: 250
Study 12736841 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-reaction trials
Number of subjects: 0
Study 12736841 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-reaction trials
Number of subjects: 0
Study 12736841 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 0
Study 10482337 — intervention group
Group type: EXPERIMENTAL
Intervention: 10000 lx cool‐white fluorescent light (active condition)
Number of subjects: 14
Study 10482337 — intervention group
Group type: COMPARATOR
Intervention: 500 lx red fluorescent light (placebo condition)
Number of subjects: 14
Study 7592271 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial hospitalization programs
Number of subjects: 95
Study 7592271 — intervention group
Group type: COMPARATOR
Intervention: Acute-care programs
Number of subjects: 95
Study 7592271 — intervention group
Group type: COMPARATOR
Intervention: Long-term programs
Number of subjects: 95
Study 1939943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 743
Study 7032457 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 0
Study 7032457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7032457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Penicillamine and Placebo)
Number of subjects: 0
Study 30918320 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 30918320 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 50
Study 28762878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg daily)
Number of subjects: 108
Study 28762878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 27288736 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM‐5 ADHD symptom descriptors
Number of subjects: 78
Study 25088629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cyclophotocoagulation (ECP) combined with phacoemulsification cataract extraction
Number of subjects: 80
Study 25088629 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract extraction alone
Number of subjects: 80
Study 21415288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel-titanium (NiTi) T-loop
Number of subjects: 12
Study 21415288 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-molybdenum alloy (TMA) T-loop
Number of subjects: 12
Study 21415288 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both T-loops
Number of subjects: 12
Study 20927415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer + its own primer (3M ESPE)
Number of subjects: 10
Study 20927415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer + Single Bond (3M ESPE)
Number of subjects: 10
Study 20927415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer + Prime and Bond 2.1 (Dentsply)
Number of subjects: 10
Study 20927415 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment with RMGIC)
Number of subjects: 10